Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk
1. Maziar Mike Doustdar appointed CEO, effective August 7, 2025. 2. Doustdar has a strong track record, previously growing sales to DKK 112 billion. 3. Novo Nordisk is merging R&D functions for better innovation focus. 4. Doustdar aims to address market challenges with a new strategy. 5. New leadership may enhance growth in diabetes and obesity sectors.